Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Principal Investigator

  • Griffith Harsh, MD

Stanford Investigator(s)

  • Scott G. Soltys, MD
  • Joel Neal, MD, PhD
  • Steven D. Chang, MD
  • Heather Wakelee
  • Iris C. Gibbs, MD, FACR


Primary Contact:
Maria Coburn
(650) 736-9551